JP2008526806A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526806A5 JP2008526806A5 JP2007549869A JP2007549869A JP2008526806A5 JP 2008526806 A5 JP2008526806 A5 JP 2008526806A5 JP 2007549869 A JP2007549869 A JP 2007549869A JP 2007549869 A JP2007549869 A JP 2007549869A JP 2008526806 A5 JP2008526806 A5 JP 2008526806A5
- Authority
- JP
- Japan
- Prior art keywords
- oxy
- methyl
- difluoro
- diene
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1-ethyl-2-methylpropyl Chemical group 0.000 claims 53
- 150000001875 compounds Chemical class 0.000 claims 25
- ZQCAOHVYAHPGEW-SCZYCMLPSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydro-3h-cyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)C(O)=O)[C@@H]4[C@@H]3CCC2=C1 ZQCAOHVYAHPGEW-SCZYCMLPSA-N 0.000 claims 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- BTDGCYZTJNQSLR-BQDNHOQLSA-N C(#N)COC(=O)C1[C@]2(C)[C@@H](CC1)[C@@H]1CCC3=CC(C=C[C@]3(C)[C@H]1CC2)=O Chemical compound C(#N)COC(=O)C1[C@]2(C)[C@@H](CC1)[C@@H]1CCC3=CC(C=C[C@]3(C)[C@H]1CC2)=O BTDGCYZTJNQSLR-BQDNHOQLSA-N 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 claims 2
- JRJULMNDORHJKG-PSWQNJPUSA-N CC1C([C@]2(C)[C@@H](C1)[C@@H]1CCC3=CC(C=C[C@]3(C)[C@H]1CC2)=O)C(=O)OCC#N Chemical compound CC1C([C@]2(C)[C@@H](C1)[C@@H]1CCC3=CC(C=C[C@]3(C)[C@H]1CC2)=O)C(=O)OCC#N JRJULMNDORHJKG-PSWQNJPUSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 150000007942 carboxylates Chemical class 0.000 claims 2
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 150000001602 bicycloalkyls Chemical group 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 239000008249 pharmaceutical aerosol Substances 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0500405A GB0500405D0 (en) | 2005-01-10 | 2005-01-10 | Novel compounds |
| GB0500405.6 | 2005-01-10 | ||
| GB0518774.5 | 2005-09-14 | ||
| GB0518774A GB0518774D0 (en) | 2005-09-14 | 2005-09-14 | Novel compounds |
| PCT/EP2006/000149 WO2006072599A2 (en) | 2005-01-10 | 2006-01-09 | Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008526806A JP2008526806A (ja) | 2008-07-24 |
| JP2008526806A5 true JP2008526806A5 (enExample) | 2009-02-12 |
| JP5281291B2 JP5281291B2 (ja) | 2013-09-04 |
Family
ID=36124037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007549869A Active JP5281291B2 (ja) | 2005-01-10 | 2006-01-09 | 新規化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7579335B2 (enExample) |
| EP (1) | EP1841780B1 (enExample) |
| JP (1) | JP5281291B2 (enExample) |
| AT (1) | ATE517908T1 (enExample) |
| WO (1) | WO2006072599A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| US20090124588A1 (en) * | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
| GB0523251D0 (en) * | 2005-11-15 | 2005-12-21 | Glaxo Group Ltd | Novel compounds |
| AR060536A1 (es) | 2006-04-20 | 2008-06-25 | Glaxo Group Ltd | Agonista del receptor de glucocorticoides y composiciones farmaceuticas |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| US20110160249A1 (en) | 2008-05-23 | 2011-06-30 | Schaab Kevin Murray | 5-lipoxygenase-activating protein inhibitor |
| JP5502858B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体 |
| WO2010057515A1 (en) * | 2008-11-21 | 2010-05-27 | Synthon B.V. | Levocetirizine by menthyl intermediate |
| ES2542551T3 (es) | 2009-03-09 | 2015-08-06 | Glaxo Group Limited | 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas |
| JP2012520257A (ja) | 2009-03-10 | 2012-09-06 | グラクソ グループ リミテッド | Ｉｋｋ２阻害剤としてのインドール誘導体 |
| JP2012520845A (ja) | 2009-03-17 | 2012-09-10 | グラクソ グループ リミテッド | Ｉｔｋ阻害剤として使用されるピリミジン誘導体 |
| WO2010107952A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2012520685A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| CA2755773A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina) |
| JP2012520686A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| JP2012521764A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| JP2012521763A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子１（ＳＴＡＴ１）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| US20120004281A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| KR20110138223A (ko) | 2009-03-27 | 2011-12-26 | 머크 샤프 앤드 돔 코포레이션 | 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제 |
| EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
| UY32571A (es) | 2009-04-24 | 2010-11-30 | Glaxo Group Ltd | Compuestos derivados de pirazol amida |
| TWI516487B (zh) | 2009-04-30 | 2016-01-11 | 葛蘭素集團有限公司 | 新穎化合物、其醫藥組合物及作為激酶活性抑制劑之用途 |
| WO2011067366A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
| EP2507226A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Novel compounds |
| US20120245171A1 (en) | 2009-12-03 | 2012-09-27 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of pi3 kinases |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| US20130274232A1 (en) | 2010-07-16 | 2013-10-17 | Cipla Limited | Pharmaceutical Compositions |
| US9326987B2 (en) | 2010-09-08 | 2016-05-03 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| PL2614058T3 (pl) | 2010-09-08 | 2015-12-31 | Glaxosmithkline Ip Dev Ltd | Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| US9149462B2 (en) | 2010-10-21 | 2015-10-06 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
| WO2012052458A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
| JP2014507458A (ja) | 2011-03-11 | 2014-03-27 | グラクソ グループ リミテッド | Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体 |
| CA2925064A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
| CA2923995A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
| CN105873934A (zh) * | 2013-12-20 | 2016-08-17 | 阿彻丹尼尔斯米德兰德公司 | 异己糖醇醚和碳酸酯的合成 |
| WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
| GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| US20190161480A1 (en) | 2016-08-08 | 2019-05-30 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| CN116194114A (zh) | 2020-03-26 | 2023-05-30 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于防止或治疗病毒感染的组织蛋白酶抑制剂 |
| KR20250134584A (ko) * | 2023-01-10 | 2025-09-11 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 글루코코르티코이드 수용체 작용제 및 이의 공액체 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1384372A (en) | 1971-01-20 | 1975-02-19 | Glaxo Lab Ltd | Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids |
| GB1438940A (en) * | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
| GB1514476A (en) | 1974-08-30 | 1978-06-14 | Glaxo Lab Ltd | Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates |
| GB2137206B (en) | 1980-02-15 | 1985-04-03 | Glaxo Group Ltd | Androstane 17-carbothioc acid derivatives |
| US4996335A (en) * | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| SE449106B (sv) | 1980-07-10 | 1987-04-06 | Otsuka Pharma Co Ltd | Steroid med anti-inflammatorisk verkan samt komposition innehallande denna |
| EP0334853B1 (en) | 1987-10-13 | 1993-06-09 | BODOR, Nicholas S. | Soft steroids having anti-inflammatory activity |
| US5990099A (en) | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| MX9301943A (es) * | 1992-04-02 | 1994-08-31 | Smithkline Beecham Corp | Compuestos. |
| ATE229001T1 (de) | 1994-06-15 | 2002-12-15 | Wellcome Found | Zwischenprodukte verwendbar in der herstellung von enzym-inhibitoren |
| US6172054B1 (en) * | 1995-06-15 | 2001-01-09 | Alcon Laboratories, Inc. | Combination therapy for lowering and controlling intraocular pressure |
| AU1970197A (en) | 1996-05-09 | 1997-11-26 | Alcon Laboratories, Inc. | Use of steroid compounds to prevent non-cancerous tissue growth |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| US6245804B1 (en) * | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| JP4219554B2 (ja) * | 1997-10-01 | 2009-02-04 | 協和発酵キリン株式会社 | ベンゾフラン誘導体 |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| ATE270278T1 (de) | 1998-03-14 | 2004-07-15 | Altana Pharma Ag | Phthalazinone pde iii/iv hemmer |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| HK1043788A1 (zh) | 1999-05-04 | 2002-09-27 | American Home Products Corporation | 四環黃體酮受體調節劑化合物及方法 |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US6263209B1 (en) | 1999-07-28 | 2001-07-17 | Motorola, Inc. | Method and apparatus in a wireless communication system for creating a learning function |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| US7101882B2 (en) | 2000-09-29 | 2006-09-05 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| JP2004522711A (ja) | 2000-11-16 | 2004-07-29 | アルコン マニュファクチャリング，リミティド | 眼内圧の低下および制御のための組み合わせ治療 |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| ES2288543T3 (es) | 2001-03-08 | 2008-01-16 | Glaxo Group Limited | Agonistas de beta-adrenorreceptores. |
| US7045658B2 (en) | 2001-03-22 | 2006-05-16 | Glaxo Group Limited | Formailide derivatives as beta2-adrenoreceptor agonists |
| CA2458534C (en) | 2001-09-14 | 2011-11-01 | Glaxo Group Limited | Phenethanolamine derivatives for treatment of respiratory diseases |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| WO2003059899A1 (en) | 2002-01-14 | 2003-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| WO2003082280A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7268152B2 (en) | 2002-03-26 | 2007-09-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| US6897224B2 (en) * | 2002-04-02 | 2005-05-24 | Schering Ag | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
| US7282591B2 (en) | 2002-04-11 | 2007-10-16 | Merck & Co., Inc. | 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| JP2005523920A (ja) | 2002-04-25 | 2005-08-11 | グラクソ グループ リミテッド | フェネタノールアミン誘導体 |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| SI1521733T1 (sl) | 2002-07-08 | 2014-10-30 | Pfizer Products Inc. | Modulatorji glukokortikoidnega receptorja |
| EP1575502B1 (en) | 2002-07-18 | 2010-01-20 | Bristol-Myers Squibb Company | Compositions and methods involving nuclear hormone receptor site ii |
| US6995181B2 (en) | 2002-07-18 | 2006-02-07 | Bristol-Myers Squibb Co. | Modulators of the glucocorticoid receptor and method |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| ATE403648T1 (de) | 2002-08-21 | 2008-08-15 | Boehringer Ingelheim Pharma | Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| MXPA05002887A (es) | 2002-09-16 | 2005-05-27 | Glaxo Group Ltd | Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de fosfodiesterasa. |
| WO2004026248A2 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| EP1554264B1 (en) | 2002-10-22 | 2007-08-08 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| DK1556342T3 (da) | 2002-10-28 | 2008-07-21 | Glaxo Group Ltd | Phenethanolaminderivat til behandling af respiratoriske sygdomme |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| US20090124588A1 (en) * | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
-
2006
- 2006-01-09 WO PCT/EP2006/000149 patent/WO2006072599A2/en not_active Ceased
- 2006-01-09 JP JP2007549869A patent/JP5281291B2/ja active Active
- 2006-01-09 EP EP06704092A patent/EP1841780B1/en active Active
- 2006-01-09 US US11/813,227 patent/US7579335B2/en active Active
- 2006-01-09 AT AT06704092T patent/ATE517908T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526806A5 (enExample) | ||
| JP2008526807A5 (enExample) | ||
| JP2008509191A5 (enExample) | ||
| CN1571664A (zh) | 经皮吸收型制剂 | |
| CN1189163C (zh) | 贴附制剂 | |
| CN1133643C (zh) | 17-β-羧基,羰基硫代以及酰胺雄甾烷衍生物的内酯衍生物 | |
| JP2003503526A5 (enExample) | ||
| JP2006506445A (ja) | 治療処置の方法 | |
| KR20100094983A (ko) | 경피 전달 시스템 | |
| JP2006528228A (ja) | サルメテロール及びシクレソニドの組合せ物 | |
| US10441597B2 (en) | Ciclesonide for the treatment of airway disease in horses | |
| US9102702B2 (en) | Steroids having 7-oxygen and 17-heteroaryl substitution-2 | |
| CN1543349A (zh) | 增强的透皮给药系统 | |
| CN1171736A (zh) | 基质型贴剂 | |
| CA2439687A1 (en) | Use of certain steroids for treatment of blood cell deficiencies | |
| MacNevin et al. | Development and screening of water-soluble analogues of progesterone and allopregnanolone in models of brain injury | |
| CN1140412A (zh) | 经皮吸收制剂 | |
| JP2023540017A (ja) | 治療用フェネチルアミン組成物およびその使用方法 | |
| JP2009001543A (ja) | ５−［３−（３−ヒドロキシフェノキシ）アゼチジン−１−イル］−５−メチル−２，２−ジフェニルヘキサンアミド塩酸塩 | |
| CN101052384A (zh) | 含有非甾体类抗炎镇痛药的非水系透皮吸收制剂 | |
| US20140271796A1 (en) | Oxybutynin-containing transdermal absorption preparation | |
| Khan et al. | Antedrugs: an approach to safer drugs | |
| EP1049471A1 (en) | Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids | |
| JP2009515844A5 (enExample) | ||
| JP2007524698A (ja) | シクレソニドとグリコピロニウムとの組合せ物 |